Dasatinib

製品コードS1021 別名:BMS-354825

Dasatinib化学構造

分子量(MW):488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 23240.00
JPY 24402.00
JPY 61420.00

文献中Selleckの製品使用例(72)

カスタマーフィードバック(13)

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

製品安全説明書

Src阻害剤の選択性比較

生物活性

製品説明 Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
ターゲット
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外試験

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe3NkBp NGPabXpFVVOR MlTwTWM2OD1yLkCwNFA4KM7:TR?= MYGxO|k2PjB6MB?=
K562 NIXIXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp M{TpV2ROW09? NUWyT5RHUUN3ME2wMlAxOSEQvF2= NE\DUWEyPzl3NkC4NC=>
M07e NHLUTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOdFczKGh? M2j2cGROW09? Ml7uTWM2OD1yLkCwNVIh|ryP NIK3RmEyPzl3NkC4NC=>
ALL3 MnP0R5l1d3SxeHnjJGF{e2G7 M{PXTVAvOc7:TR?= MmHkO|IhcA>? M2npPWROW09? M3jkdGlEPTB;MD6wNFA1KM7:TR?= MUSxPVg5QTV2MB?=
CML MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;we|kzOCCvaX6= NX7OcXZiTE2VTx?= NEjmWmhKSzVyPUCuNFAyKM7:TR?= NILKXYcyQTJzOUCxOi=>
BA/F3 M4j6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi5O|IhcA>? MUTEUXNQ MX7JR|UxRTZwNUi5JO69VQ>? NWHYSpExOjNyOEi2OFQ>
BA/F3 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjYe4R7PzJiaB?= NIeyR2RFVVOR M1PyeGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN MoX0NlMxQDh4NES=
BA/F3 NGjQTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV23NkBp MVfEUXNQ M1zXSGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? M1HsS|I{ODh6NkS0
BA/F3 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYiwUXF2PzJiaB?= MkS1SG1UVw>? MmXYTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP NWf6OHBVOjNyOEi2OFQ>
BA/F3 NVi2SXpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvwT244OiCq Mlj6SG1UVw>? NHyx[25KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= MUSyN|MxOTdyMx?=
BA/F3 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTqO|IhcA>? NYfF[otITE2VTx?= NVzhfWM3UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= NHq1fHIzOzNyMUewNy=>
BA/F3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jTO|czKGh? MXLEUXNQ NViwbJNKUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= MUKyN|MxOTdyMx?=
BA/F3 M3nwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLpO|IhcA>? NXHabGFuTE2VTx?= NVXxSolXUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MV:yN|MxOTdyMx?=
BA/F3 NYDkdZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWyN5hHPzJiaB?= MlPVSG1UVw>? NV3FTmIyUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= M2LuNFI{OzBzN{Cz
BA/F3 M1XofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[5XlczKGh? NUG3RWppTE2VTx?= NWTPZVlLUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? NHflSmQzOzNyMUewNy=>
BA/F3 M121cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjKO|IhcA>? NITiVohFVVOR MXzJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NVPpTHJxOjN|MEG3NFM>
BA/F3 M4\BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjBNZA4OiCq NXrpXHBZTE2VTx?= MYPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> NIjGd3IzOzNyMUewNy=>
BA/F3 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDvO|IhcA>? NGHZfXRFVVOR MkLhTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP M1z6NVI{OzBzN{Cz
T cell MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[3NkBp M1LVZmROW09? MXfJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> MmrDNVcyPTR3MUK=
WiDr MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkVFczKGh? MWPEUXNQ NYHjOm5KUUN3ME2wMlA2OiEQvF2= NWLyd|lwOTV4MUW1NVI>
PC3 NWrzVGRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X0ZVczKGh? NX3pVIh[TE2VTx?= M3HlU2lEPTB;MD6wNFk1KM7:TR?= NX\TOoxPOTV4MUW1NVI>
MDA-MB-231 NX\1NI13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO3NkBp MVPEUXNQ Mnn3TWM2OD1yLkCxNkDPxE1? M{DnSFE2PjF3NUGy
Hs578T NXOwUId3S3m2b4TvfIlkKEG|c3H5 Mor1O|IhcA>? NH:4UVVFVVOR MWrHTVUxRTBwMEOg{txO M2X5UVI1ODF3M{K3
HMEC M4\vTmN6fG:2b4jpZ{BCe3OjeR?= MWq3NkBp MULEUXNQ NUDneGFDT0l3ME2xMlgh|ryP M4eyZ|I1ODF3M{K3
DU145 NIe4UXpEgXSxdH;4bYMhSXO|YYm= NHTydoY4OiCq NUfxWHpCTE2VTx?= MkGzS2k2OD1yLkG2JO69VQ>? NH61doszPDBzNUOyOy=>
U251 MV\DfZRwfG:6aXOgRZN{[Xl? M{LnflczKGh? NX:wU25[TE2VTx?= M1X5XGdKPTB;Mj64NUDPxE1? NFjGUJMzPDBzNUOyOy=>
NCI60 NIXBbnFEgXSxdH;4bYMhSXO|YYm= MmHhO|IhcA>? MWXEUXNQ NH7KOWpIUTVyPUWuO{DPxE1? NUHTRmNQOjRyMUWzNlc>
MALME-3M NVjsRnhTS3m2b4TvfIlkKEG|c3H5 Ml\XO|IhcA>? NIPzTG9FVVOR M175VGdKPTB;Nj62NUDPxE1? NGHWb2ozPDBzNUOyOy=>
KM12 Mn33R5l1d3SxeHnjJGF{e2G7 NW[xN3BkPzJiaB?= MX7EUXNQ M4nMbGdKPTB;Nz60OEDPxE1? NVS3fHpNOjRyMUWzNlc>
SW620 MW\DfZRwfG:6aXOgRZN{[Xl? MlfXO|IhcA>? MU\EUXNQ M{jIVWdKPTB;OD60N{DPxE1? NIDPU|kzPDBzNUOyOy=>
RXF 393NL NX21dXBwS3m2b4TvfIlkKEG|c3H5 NXXFVFVvPCCmYYnz NIruNVJFVVOR MXHJR|UxRTBwMEKxO{DPxE1? NIrSUIgzOzJ3M{C3OC=>
LXFA 983L MVPDfZRwfG:6aXOgRZN{[Xl? MX[0JIRigXN? NFHiZVJFVVOR M1[w[mlEPTB;MD6wOVY2KM7:TR?= NVS2XpNKOjN{NUOwO|Q>
PRXF DU145 MXPDfZRwfG:6aXOgRZN{[Xl? MXO0JIRigXN? NFe1bVlFVVOR NF21V|hKSzVyPUCuNFYzOyEQvF2= NFHae24zOzJ3M{C3OC=>
PAXF 1657L NYnXWGZJS3m2b4TvfIlkKEG|c3H5 MoXTOEBl[Xm| MUPEUXNQ NGiwPHFKSzVyPUCuNVIyKM7:TR?= NYrTUmtFOjN{NUOwO|Q>
CXF 1103L NHTyTW5EgXSxdH;4bYMhSXO|YYm= MUG0JIRigXN? M1Hqd2ROW09? NFvlW2FKSzVyPUSuN|Yh|ryP NX[2OWxmOjN{NUOwO|Q>
GXF251L NEPxO5REgXSxdH;4bYMhSXO|YYm= MnLuOEBl[Xm| MmLWSG1UVw>? Ml;3TWM2OD1{LkK1JO69VQ>? NEHTdJkzOzJ3M{C3OC=>
NCI-H23 NInk[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXIc5JTPzJiaB?= M1f5NWROW09? NYS4UZplUUN3ME2yMlI4KM7:TR?= NF\lT|gzOzV{MUCyNC=>
HCT116 NEjVbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvO|IhcA>? NIHoUlRFVVOR MlG3TWM2OD1{LkOg{txO NYH3XWdjOjN3MkGwNlA>
MCF7 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tme|czKGh? NUTU[YdrTE2VTx?= MUHJR|UxRTJwNUeg{txO NXzRcoN2OjN3MkGwNlA>
NCI-H460 NY\1c4plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TMWFczKGh? MVHEUXNQ M{K4OWlEPTB;OD65PUDPxE1? MmLyNlM2OjFyMkC=
DLD1 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6yNoo4OiCq NV;yTYtITE2VTx?= MUjJR|UxRTRwNjFOwG0> M1X2cFI{PTZ5OU[w
NCI-H661 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1POcFczKGh? MXzEUXNQ NUHrbGFiUUN3ME23Mlgh|ryP MmnDNlM2Pjd7NkC=
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NkBp MXXEUXNQ MU\JR|UxRThwMjFOwG0> MX6yN|U3Pzl4MB?=
U937 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXy3NkBp MUfEUXNQ MlrRTWM2OD1zMj6yJO69VQ>? M1;uPFI{PTZ5OU[w
HEK293 M1X0SWZ2dmO2aX;uJGF{e2G7 MmLzNVDDqM7:TR?= MmPKSG1UVw>? MX7JcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= MXSyNlc4ODZzMB?=
HUVEC M1HnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCwMlE2yqEQvF2= NWq1Z4JyPzJiaB?= MnLNSG1UVw>? MW\JcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= NU\QVGpuOjJ6NUO5PVM>
HUVEC M3rWOmZ2dmO2aX;uJGF{e2G7 NETNbJIyPcLizszN NXH3Rm9XPzJiaB?= MVTEUXNQ NHfpcpVKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? NUjI[mlCOjJ6NUO5PVM>
Plasmodium falciparum NXW1PJdCTnWwY4Tpc44hSXO|YYm= M{HLVVExyqEQvF2= NEjWb44yPSCvaX6= NF7pemlFVVOR M4\qUWlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? M2rUbFI1PTVyM{Ow
PC3 MVnGeY5kfGmxbjDBd5NigQ>? MUmwMlEh|ryP M4DIW|UhcA>? NWTZe4I3TE2VTx?= NYjJR2RQUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MYSxPVQ3Ojl5NR?=
DU145 NUjUdIlwTnWwY4Tpc44hSXO|YYm= NES3VZoxNjFizszN NH6zOIk2KGh? M3XIWmROW09? NE[2e25KdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> NVLRUXc3OTl2NkK5O|U>
PC3 NIrxN5VMcW6jc3WgRZN{[Xl? NUDDTWNDOC5zIN88US=> NWjQcHo{PSCq NIHhTlBFVVOR MXHJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P NVjEXWw2OTl2NkK5O|U>
DU145 NEm5SGpMcW6jc3WgRZN{[Xl? MVywMlEh|ryP NYGxVmdMPSCq NYfEVFNSTE2VTx?= M1HhTmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MknGNVk1PjJ7N{W=
PC3 MoP4T4lv[XOnIFHzd4F6 MYqwMlEh|ryP NGLuO4I2KGh? NYLpfVBvTE2VTx?= M2[1fGlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? MVqxPVQ3Ojl5NR?=
DU145 M3nFVGtqdmG|ZTDBd5NigQ>? MXmwMlEh|ryP NU\tUlZMPSCq MknaSG1UVw>? NUfnN2hxUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= NEnKN2MyQTR4Mkm3OS=>
Huh7 NFq4R3NCdnSrdnnyZYwhSXO|YYm= NITPeGMzNjVizszN MnTSOEBl[Xm| M2HHTGROW09? M1XzS2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NHroTFkyPzN4ME[3Oi=>
C6/36 NGXwNZZCdnSrdnnyZYwhSXO|YYm= NHzaboozNjVizszN NET5OpY1KGSjeYO= NFvIXmlFVVOR M3nkW2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? M3m3V|E4OzZyNke2
U937 M2LNRmZ2dmO2aX;uJGF{e2G7 MonCNUDPxE1? NV7WfXV6OSCq MWTEUXNQ M4L1XnJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| MofGNVc3QDRyOUm=
U937 NEe5blBHfW6ldHnvckBCe3OjeR?= MkOyNUDPxE1? NELwVIoyKGh? NIXWW|JFVVOR Ml7PVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> M133T|E4Pjh2MEm5
murine mast cell M33YN2Z2dmO2aX;uJGF{e2G7 MYGxJO69VQ>? MnXRNlQhcA>? MUDEUXNQ NHfBbmdKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= MWSxO|Y5PDB7OR?=
BV-173 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMECwNFAxOTB7IN88US=> MnTlV2FPT0WU
K-562 NWHMfplyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KyNWlEPTB;MD6wNFAxODB{Nk[g{txO MojiV2FPT0WU
BL-70 NYLP[WIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFix[ItKSzVyPUCuNFAxODByOEKyJO69VQ>? NEfF[JFUSU6JRWK=
EM-2 NGfCS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TT[WlEPTB;MD6wNFAxODFyODFOwG0> MnTxV2FPT0WU
LAMA-84 M3ywO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SzdmlEPTB;MD6wNFAxODN{MTFOwG0> NWH6NWNNW0GQR1XS
MEG-01 NULkenBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMECwNFA6QCEQvF2= NX7iTHlwW0GQR1XS
EoL-1-cell NWXxUVR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMECwNFE{OSEQvF2= NYnvfZlGW0GQR1XS
CTV-1 NVrVR2QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTJ[YhRUUN3ME2wMlAxODB2MESg{txO MorOV2FPT0WU
TE-15 M2HkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEC1PFkh|ryP MWrTRW5ITVJ?
NOS-1 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjmXJFKSzVyPUCuNFA3OTNizszN NFnY[ZNUSU6JRWK=
D-336MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTSTWM2OD1yLkCwOlMh|ryP MUfTRW5ITVJ?
LB1047-RCC M{LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvQTWM2OD1yLkCwPVg6KM7:TR?= MmrxV2FPT0WU
LB996-RCC NHL0[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEC5PVEh|ryP NIDrO5pUSU6JRWK=
SW982 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKwV2Y3UUN3ME2wMlAyOTF3IN88US=> MlfXV2FPT0WU
TK10 NIq4N3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfnWGxKSzVyPUCuNFEyPzRizszN NUS2XmxUW0GQR1XS
A704 M1W1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PGWWlEPTB;MD6wNVQ6OSEQvF2= NEjzVXNUSU6JRWK=
TE-8 NETRTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPoTWM2OD1yLkCxOVc3KM7:TR?= NXPvU3pWW0GQR1XS
DOHH-2 M1v3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\2O2hLUUN3ME2wMlAyPzF7IN88US=> M2npPHNCVkeHUh?=
HOP-62 M{PPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEG4N|Qh|ryP MUHTRW5ITVJ?
TE-12 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEG4OlEh|ryP MUHTRW5ITVJ?
KGN M3TnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jCOWlEPTB;MD6wNVk1OiEQvF2= MmXxV2FPT0WU
NCI-H1648 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLXclcxUUN3ME2wMlAzODFzIN88US=> NIjjN5dUSU6JRWK=
OS-RC-2 M2K0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQOZdKSzVyPUCuNFIxOyEQvF2= MmTUV2FPT0WU
GB-1 M3z6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEKxOVch|ryP MU\TRW5ITVJ?
RXF393 NFG5W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33FdWlEPTB;MD6wNlM2PyEQvF2= MoHRV2FPT0WU
LC-2-ad M3PpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rPXWlEPTB;MD6wNlU5PiEQvF2= NXXR[ndMW0GQR1XS
KS-1 M1Sybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzyOlM5UUN3ME2wMlAzPzNizszN MYXTRW5ITVJ?
ETK-1 NXW4[5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEK4N|Ih|ryP NXHnTodXW0GQR1XS
SW954 NXf4Opc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\lTWM2OD1yLkCyPVI4KM7:TR?= NX3hO|VSW0GQR1XS
Becker NWfqUo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i2dGlEPTB;MD6wN|AxOyEQvF2= NVjhbHFwW0GQR1XS
MZ1-PC NEDmNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEOxNVkh|ryP NF;INmJUSU6JRWK=
ES6 NVr1U253T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DSPGlEPTB;MD6wN|E6OyEQvF2= NV7yZ|NPW0GQR1XS
KURAMOCHI M1voTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H4N2lEPTB;MD6wN|Q5PyEQvF2= MXjTRW5ITVJ?
CGTH-W-1 M{jXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D1RWlEPTB;MD6wN|U1QCEQvF2= NE\BPI9USU6JRWK=
VA-ES-BJ M3nwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMSWZOUUN3ME2wMlA{QTB{IN88US=> Ml7aV2FPT0WU
LXF-289 M4HONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nrT2lEPTB;MD6wN|k2PiEQvF2= MV;TRW5ITVJ?
MPP-89 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Zd|VpUUN3ME2wMlA1ODR7IN88US=> NH3hRplUSU6JRWK=
SW872 NH7iOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7FUZVlUUN3ME2wMlA1OTZzIN88US=> NUS1WIJpW0GQR1XS
SNB75 M2Xy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz3TWM2OD1yLkC0OFM2KM7:TR?= MlG0V2FPT0WU
PSN1 NHvNd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELrb|ZKSzVyPUCuNFQ1PzRizszN MV;TRW5ITVJ?
LB831-BLC NF3NbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMES2NFkh|ryP MmLIV2FPT0WU
MFH-ino MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfHTWM2OD1yLkC0O|I1KM7:TR?= M3LjdnNCVkeHUh?=
TGBC24TKB NF;Yc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMES3OlEh|ryP NIH6To5USU6JRWK=
A388 NYfHNYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i4NWlEPTB;MD6wOVA6PSEQvF2= NU[0TXM{W0GQR1XS
BB30-HNC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP0TWM2OD1yLkC1OFM4KM7:TR?= MX3TRW5ITVJ?
GI-ME-N M1HGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3MPXhKSzVyPUCuNFYyOThizszN M{nlT3NCVkeHUh?=
TGBC1TKB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDzWZdKSzVyPUCuNFYyPjRizszN MWHTRW5ITVJ?
TE-10 M2CzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[5RYtKSzVyPUCuNFY{PTdizszN M3ru[3NCVkeHUh?=
A498 NGfz[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEeyPFQh|ryP MVzTRW5ITVJ?
TE-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrHZ49KSzVyPUCuNFc5PThizszN NYnKTlVlW0GQR1XS
BB65-RCC NYDsPW1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfsXXFLUUN3ME2wMlA5OjJ5IN88US=> NGDyZVNUSU6JRWK=
C2BBe1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5TWM2OD1yLkC4N|A5KM7:TR?= MoDOV2FPT0WU
NCI-H747 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X1cWlEPTB;MD6wPFM3OiEQvF2= NYPxV|c4W0GQR1XS
IST-MES1 M2LBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHrUGtzUUN3ME2wMlA5PTV{IN88US=> MlvkV2FPT0WU
KALS-1 M2r0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nHfGlEPTB;MD6wPVQ6KM7:TR?= M3XRT3NCVkeHUh?=
GCIY M{LRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDkTHlKSzVyPUCuNFk3PTZizszN MV7TRW5ITVJ?
RL95-2 NHP6SmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMUCzPEDPxE1? NH;STmxUSU6JRWK=
TE-1 M17xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DtR2lEPTB;MD6xNFU1KM7:TR?= NVnGcIRVW0GQR1XS
NCI-H1355 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPSTWM2OD1yLkGxNFI5KM7:TR?= MmX3V2FPT0WU
SW962 NWLOWYg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXtWItKSzVyPUCuNVEzQTJizszN NVnnRVR7W0GQR1XS
KLE NVq1[mt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrWd3VKSzVyPUCuNVE{OTdizszN NX6wcI9wW0GQR1XS
MC116 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMUG0NUDPxE1? NIfKVJVUSU6JRWK=
NMC-G1 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rjbGlEPTB;MD6xNVYxPiEQvF2= MXHTRW5ITVJ?
KU812 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUG4PFMh|ryP MWXTRW5ITVJ?
COLO-829 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[xeGlEPTB;MD6xNlIyOyEQvF2= MnzDV2FPT0WU
NTERA-S-cl-D1 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HtT2lEPTB;MD6xNlI5OyEQvF2= MVrTRW5ITVJ?
IST-MEL1 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrWNGJ7UUN3ME2wMlE{PDVizszN NEXsOYlUSU6JRWK=
MLMA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfzTWM2OD1yLkG0NFMzKM7:TR?= M4XNVnNCVkeHUh?=
LS-123 M{T6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37JT2lEPTB;MD6xOFA3PCEQvF2= M1LHcXNCVkeHUh?=
LB2518-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnRTWM2OD1yLkG0NVYzKM7:TR?= NVrYb2xoW0GQR1XS
NB69 NYDhSIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqwRZZtUUN3ME2wMlE1PDN4IN88US=> NXzwOndzW0GQR1XS
8-MG-BA MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD1yLkG1OFU5KM7:TR?= NXTHSmpjW0GQR1XS
K5 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:4WYg4UUN3ME2wMlE3PDh7IN88US=> NFK0PVRUSU6JRWK=
KINGS-1 NXLqfotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTRTWM2OD1yLkG2OlY3KM7:TR?= M1HYVHNCVkeHUh?=
SF268 NXjRR2lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMUe0NFQh|ryP M1jQTXNCVkeHUh?=
PF-382 NF\tR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HyVWlEPTB;MD6xO|Y4QCEQvF2= NVHTRW5PW0GQR1XS
SH-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7QTWM2OD1yLkG4OFE{KM7:TR?= M{HWTXNCVkeHUh?=
NALM-6 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnycWQxUUN3ME2wMlE6Ojl3IN88US=> M3nHfXNCVkeHUh?=
CP66-MEL NYmwTFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HVWWlEPTB;MD6xPVU{OSEQvF2= Mnq4V2FPT0WU
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHTSplVUUN3ME2wMlE6QTh5IN88US=> NWn0fmFkW0GQR1XS
CP67-MEL NVy3UYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkC0PFgh|ryP NWOwRWV2W0GQR1XS
DSH1 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\QVGt1UUN3ME2wMlI1ODBzIN88US=> MWrTRW5ITVJ?
HCE-4 M{Pae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;WTWM2OD1yLkK2OFM6KM7:TR?= NICzVlNUSU6JRWK=
MZ2-MEL NFr2fpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrqTWM2OD1yLkK4OVM4KM7:TR?= NEPWUnNUSU6JRWK=
BL-41 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\uc|VoUUN3ME2wMlI6OTJ|IN88US=> MmqzV2FPT0WU
HUTU-80 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDzTWM2OD1yLkOxOFIh|ryP NUPyfotLW0GQR1XS
LOXIMVI NIDqbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDNR41KSzVyPUCuN|E2ODNizszN MVTTRW5ITVJ?
no-10 NV[2WZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fuRWlEPTB;MD6zNVk{OSEQvF2= NE\PZ2pUSU6JRWK=
KARPAS-422 NULMemRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL5TWM2OD1yLkOzPVk4KM7:TR?= MWfTRW5ITVJ?
SW684 NV\6Z5dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;xU2lEPTB;MD6zOFk5KM7:TR?= M{PBc3NCVkeHUh?=
SF126 NIHieWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT1TWM2OD1yLkO1OFEh|ryP MXjTRW5ITVJ?
D-263MG M{fLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy2ZYhNUUN3ME2wMlM3OjJ2IN88US=> MnvzV2FPT0WU
OVCAR-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjqfWZKSzVyPUCuN|c1OzNizszN MUjTRW5ITVJ?
BB49-HNC NEn2TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{i1PVkh|ryP Mmj5V2FPT0WU
ONS-76 NHPETlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV21cWk2UUN3ME2wMlQzQTVzIN88US=> NXXDW5E1W0GQR1XS
MZ7-mel NHKydY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;z[Y5KSzVyPUCuOFc6OTFizszN Mnj5V2FPT0WU
RCC10RGB NF\ZeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ju[GlEPTB;MD60PVEyKM7:TR?= MlXvV2FPT0WU
BOKU MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzjTWM2OD1yLkS5NVM{KM7:TR?= NIjlWWNUSU6JRWK=
no-11 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfGTWM2OD1yLkWwNlI5KM7:TR?= NHjUZ3RUSU6JRWK=
IST-SL2 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnhdplKSzVyPUCuOVA{ODJizszN M1qyXXNCVkeHUh?=
RKO NH3pRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XoT2lEPTB;MD61Nlk3PiEQvF2= MYPTRW5ITVJ?
HT-144 M4fCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTmfXZKSzVyPUCuOVM3ODlizszN MYPTRW5ITVJ?
NCI-H446 M13TfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwNkK3OkDPxE1? MlPjV2FPT0WU
QIMR-WIL MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW0TJFKSzVyPUCuO|A3OjlizszN MkfaV2FPT0WU
MHH-PREB-1 NXjscohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof6TWM2OD1yLke0OFY6KM7:TR?= NWrKTlBwW0GQR1XS
EW-16 M{ToW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK3N2Q2UUN3ME2wMlc3OTd6IN88US=> MWDTRW5ITVJ?
EW-24 M17uT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7VW2hKSzVyPUCuO|gyPjVizszN Mn[5V2FPT0WU
LB373-MEL-D NVnrPHRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XU[WlEPTB;MD64NlUxQCEQvF2= M4[3d3NCVkeHUh?=
TE-9 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwOEe1N|Ih|ryP NFjp[4xUSU6JRWK=
A3-KAW MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTPTWM2OD1yLkm4OFUzKM7:TR?= NFzJWIZUSU6JRWK=
A101D M4XQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\xc3luUUN3ME2xMlA{ODR|IN88US=> NV7LSZR3W0GQR1XS
OCUB-M M3H5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\u[GRKSzVyPUGuNFQ1OTJizszN M2S1XXNCVkeHUh?=
ES4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnjTWM2OD1zLkC1NVQ2KM7:TR?= M17BV3NCVkeHUh?=
TE-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MleyTWM2OD1zLkKxNlI3KM7:TR?= MXPTRW5ITVJ?
D-502MG M1;x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fwNWlEPTB;MT6yN|M4PiEQvF2= NUfMUYRHW0GQR1XS
KNS-42 M4PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwMkS0NVIh|ryP MoixV2FPT0WU
SNU-C2B M2jHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfWTWM2OD1zLkOwOVg6KM7:TR?= NFHmbodUSU6JRWK=
NCI-H1838 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnOSGlZUUN3ME2xMlMxPzN|IN88US=> NHvKVYFUSU6JRWK=
NKM-1 NGTD[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwM{C4OVkh|ryP MXnTRW5ITVJ?
GI-1 NIHvW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PZTWlEPTB;MT6zOlIzKM7:TR?= MUnTRW5ITVJ?
NB5 NYnGVFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnkUodDUUN3ME2xMlM6QDJ5IN88US=> Mor1V2FPT0WU
CAS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfKTWM2OD1zLkSwPVkzKM7:TR?= NFLqem5USU6JRWK=
HCE-T MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTXWGlvUUN3ME2xMlU3PzF2IN88US=> NFjFNIFUSU6JRWK=
SBC-1 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonXTWM2OD1zLkW3PVg1KM7:TR?= MVnTRW5ITVJ?
JiyoyeP-2003 NELVfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T5W2lEPTB;MT63N|Q3PiEQvF2= MWLTRW5ITVJ?
TE-5 NVPuUmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwN{mxN|kh|ryP MkP0V2FPT0WU
CAN MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTSTWM2OD1zLkiyNlUzKM7:TR?= M1\YZ3NCVkeHUh?=
SK-UT-1 NYroWHZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPheGpKSzVyPUKuNVY3QTNizszN MUjTRW5ITVJ?
JVM-2 NITzNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;3VXRKSzVyPUKuN|YzQDRizszN M4TBUnNCVkeHUh?=
LB771-HNC NX\BNHpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;qVWlEPTB;Mj61O|U2OSEQvF2= NEnOUphUSU6JRWK=
NCCIT MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vhdWlEPTB;Mj64OlYyPiEQvF2= M4fMRnNCVkeHUh?=
NCI-H2126 NEC2e3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSxTWM2OD1{Lki3OVUzKM7:TR?= M3S4RXNCVkeHUh?=
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Wzb2lEPTB;Mz6wOVc1OSEQvF2= MX\TRW5ITVJ?
SK-LMS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXXVW5sUUN3ME2zMlEyQDh4IN88US=> NIDPNIxUSU6JRWK=
ARH-77 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;kRpVKSzVyPUOuOFY6OTVizszN NFvycVJUSU6JRWK=
NB17 M1Ps[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rkOmlEPTB;Mz62N|g1PyEQvF2= NYHZNZFVW0GQR1XS
A253 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjVTWM2OD1|LkezNlQ3KM7:TR?= MoTBV2FPT0WU
OPM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjiVY5ZUUN3ME20MlI4Pjh3IN88US=> NVTrVJg{W0GQR1XS
MV-4-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHIZndKSzVyPUSuN|Y1PTRizszN NV7teXJQW0GQR1XS
SR NXKyVmczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrEfHR6UUN3ME20MlQ6QTV2IN88US=> MW\TRW5ITVJ?
KG-1 NH\OTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH74d2lKSzVyPUSuOlA5PDVizszN MX3TRW5ITVJ?
OCI-AML2 NEH6SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTVwOE[xOVQh|ryP M3\5SHNCVkeHUh?=
D-247MG MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnUTWM2OD14LkGyOVE6KM7:TR?= M1qyd3NCVkeHUh?=
DJM-1 M4fMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XWPWlEPTB;Nj60PFU2QCEQvF2= M3K5PHNCVkeHUh?=
RPMI-6666 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTdwMkewOlch|ryP NETYR45USU6JRWK=
KARPAS-45 NFXEOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm1TWM2OD15LkWxOlcyKM7:TR?= NYX4XW1pW0GQR1XS
LP-1 M3v1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTdwNUS3PFIh|ryP Ml[wV2FPT0WU
RS4-11 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HFN2lEPTB;Nz62OVc5PyEQvF2= MkDNV2FPT0WU
DU-4475 M3z5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTkdJp7UUN3ME24MlIyPjV{IN88US=> M{XldHNCVkeHUh?=
MONO-MAC-6 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHjeYRiUUN3ME24MlI4ODZ4IN88US=> M3KxeXNCVkeHUh?=
NCI-SNU-16 NYq5eXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHHd29{UUN3ME24MlU3OTJ6IN88US=> MnKwV2FPT0WU
SJSA-1 M1rOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRThwN{K4NFUh|ryP M4O2fHNCVkeHUh?=
MMAC-SF NEPPWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfrTWM2OD16Lke5N|A4KM7:TR?= MkPlV2FPT0WU
SK-NEP-1 NFnvTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRThwOEmxOVUh|ryP NWHpPW5DW0GQR1XS
J-RT3-T3-5 M2C5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO4R5lmUUN3ME24Mlk3PTJ7IN88US=> MVPTRW5ITVJ?
SKM-1 NFS2Z4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\VNplKSzVyPUmuNFE4OzRizszN MoTpV2FPT0WU
LB2241-RCC NFnPSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq2V2pKSzVyPUmuNFIxOTJizszN NXvNOZdWW0GQR1XS
SIG-M5 M4jndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rwcmlEPTB;OT6wNlQ6OyEQvF2= M3fvUnNCVkeHUh?=
EVSA-T MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K0V2lEPTB;OT6yO|c6OyEQvF2= NHPLSGJUSU6JRWK=
GT3TKB M{\PU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37XNGlEPTB;OT6zOVU1PiEQvF2= MYrTRW5ITVJ?
NB6 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXJSodKSzVyPUmuPVIzPTlizszN MYHTRW5ITVJ?
EHEB NH;CbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFyLkC2OVYh|ryP MWfTRW5ITVJ?
HEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPa[|hKSzVyPUGwMlQ4PzZizszN NWrKeFFOW0GQR1XS
ALL-PO NIXwUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFyLke5N|gh|ryP MkHHV2FPT0WU
TGW NXTuUHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFzLkK4Nlgh|ryP M{LCbnNCVkeHUh?=
BC-3 NXvIN2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XubmlEPTB;MUKuNVE{QCEQvF2= MnO4V2FPT0WU
IA-LM M1X1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\GS2lEPTB;MUKuOFQ1PSEQvF2= MnvWV2FPT0WU
UACC-257 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjSe21KSzVyPUGyMlkyQThizszN MkXlV2FPT0WU
KP-N-YS NEnCSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3jTWM2OD1zMj65Nlg{KM7:TR?= Mlu0V2FPT0WU
Raji NEf1UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\lbWc2UUN3ME2xN{44PDl5IN88US=> NU\0bnYxW0GQR1XS
SF539 NHH3fmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF|Lki1OVch|ryP NYfRXJBkW0GQR1XS
DMS-153 M2nLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DrZWlEPTB;MUSuNFAzQCEQvF2= M3z2dHNCVkeHUh?=
L-540 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vQc2lEPTB;MUWuNFY4OiEQvF2= MlLNV2FPT0WU
MN-60 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn34TWM2OD1zNT6xPVc6KM7:TR?= NGLJTI9USU6JRWK=
RPMI-8866 M{PJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LFZWlEPTB;MUeuOFQ2PCEQvF2= MmLjV2FPT0WU
NCI-H510A NHrteoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\zNVZLUUN3ME2xPU4{QTd|IN88US=> MUHTRW5ITVJ?
NB13 M2\XSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnlTWM2OD1zOT60PFc4KM7:TR?= MmDUV2FPT0WU
HAL-01 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLFTWM2OD1zOT63OVQ{KM7:TR?= NGnXS5ZUSU6JRWK=
NCI-H720 NFXyV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPhUGJKSzVyPUKwMlI4OzNizszN MVPTRW5ITVJ?
REH NWnPUZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\0d2lEPTB;MkCuOlM2PyEQvF2= NFK5WpBUSU6JRWK=
KNS-81-FD Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[yRmQzUUN3ME2yN{4yPDZizszN M4nmXHNCVkeHUh?=
HC-1 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqwTWM2OD1{ND61OVUyKM7:TR?= NUfwXGZKW0GQR1XS
NCI-H2141 M3PqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD5b5lvUUN3ME2yOE44PzV2IN88US=> MmK0V2FPT0WU
MOLT-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D6cGlEPTB;Mk[uOlc2OyEQvF2= NUnhTFBPW0GQR1XS
OMC-1 M1jmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3GTWM2OD1{Nz6xOFIzKM7:TR?= Mo\oV2FPT0WU
LC-1F NFnhTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPeXhKSzVyPUK3MlMzPDVizszN MYDTRW5ITVJ?
NCI-H1304 M1LUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\3ZnBKUUN3ME2yPE4yPjJ6IN88US=> NVPrcIk1W0GQR1XS
BC-1 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3MO41KSzVyPUK4MlY2OSEQvF2= NXHOXY5vW0GQR1XS
NCI-H64 NWX1cGk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jVZ2lEPTB;MkmuOlI2OyEQvF2= M1;sSXNCVkeHUh?=
MOLT-16 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW2TnVlUUN3ME2yPU43Ojl{IN88US=> M{Hkb3NCVkeHUh?=
U-87-MG NIDldWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPCTWM2OD1|MD63OlYh|ryP M2qxNnNCVkeHUh?=
GAK NXPHT|M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[wcHFKSzVyPUOxMlI3QDZizszN MoXpV2FPT0WU
ES8 NUnjVlQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m2VWlEPTB;M{KuNVI2OiEQvF2= NILFPWhUSU6JRWK=
HCC1599 M1L6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD1|Mj6zN|I2KM7:TR?= M17uWHNCVkeHUh?=
EB-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjzRodKSzVyPUO0MlMyOTdizszN Ml:4V2FPT0WU
HCC1187 NF6wRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PrXmlEPTB;M{WuPFA2OiEQvF2= NFPvTXJUSU6JRWK=
SK-PN-DW MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvhTWM2OD1|Nj6xPVQ{KM7:TR?= MoH4V2FPT0WU
JVM-3 NF7QbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LEd2lEPTB;M{euNlM{QCEQvF2= M3\XUXNCVkeHUh?=
HCC2157 NV;rOmxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[xWFRFUUN3ME2zO{46QTR4IN88US=> NUT2RZZGW0GQR1XS
A4-Fuk MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvvRoRKSzVyPUO4MlExODlizszN MYHTRW5ITVJ?
COR-L279 NEfHNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELBcGZKSzVyPUSwMlI5PTFizszN MVfTRW5ITVJ?
DEL NUHrN41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRzLkmwPFYh|ryP NXX3SJRCW0GQR1XS
NCI-H1395 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfndlJKSzVyPUSyMlAyPjNizszN M{\lTXNCVkeHUh?=
MHH-NB-11 NV\Re3c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInOcplKSzVyPUSzMlA5OThizszN NHHIWFNUSU6JRWK=
NCI-H2107 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXsTm04UUN3ME20N{41QDR4IN88US=> MlHnV2FPT0WU
NEC8 NGC5O4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonwTWM2OD12ND6zN|Yh|ryP NETrWmFUSU6JRWK=
COLO-684 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH1UVV3UUN3ME20Ok4zOjV6IN88US=> MkmzV2FPT0WU
LS-411N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR6LkS3OFgh|ryP MUHTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
細胞試験:

[1]

+ 展開
  • 細胞株: Ba/F3 cell lines
  • 濃度: ~32 nM
  • 反応時間: 72 hours
  • 実験の流れ:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • 製剤: DMSO
  • 投薬量: 30 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管
in solvent
別名 BMS-354825

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Not yet recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC October 2018 Phase 2
NCT03516279 Not yet recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group August 12 2018 Phase 2
NCT03595917 Recruiting B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL Marlise R. Luskin|Novartis|Dana-Farber Cancer Institute July 24 2018 Phase 1
NCT03654768 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive Southwest Oncology Group|National Cancer Institute (NCI) July 20 2018 Phase 2
NCT03560908 Recruiting Relapsed AML|T(8;21)|C-KIT Mutation Institute of Hematology & Blood Diseases Hospital July 1 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 質問2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Srcシグナル伝達経路

Src Inhibitors with Unique Features

相関Src製品

Tags: Dasatinibを買う | Dasatinib ic50 | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib化学構造 | Dasatinib分子量 | Dasatinib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID